Form 4: Brainstorm Cell Therapeutics CEO Receives Stock Awards
SEC Form 4 Filing
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, received restricted stock awards and is deemed the beneficial owner of shares held by ACCBT Corp. and ACC International Holdings Ltd.
Summary
- Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, received 305,198 shares of common stock on March 11, 2024, as part of a restricted stock award.
- The restricted stock awards will vest in equal yearly installments over two years, starting on the first anniversary of the grant date.
- Lebovits is also deemed the beneficial owner of 1,933,794 shares of Common Stock owned by ACCBT Corp. and 67,053 shares of Common Stock owned by ACC International Holdings Ltd.
- Following the reported transactions, Lebovits directly owns 598,493 shares of Common Stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of restricted stock awards to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
This type of equity compensation is common in the biotech industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Biogen, and Gilead Sciences routinely grant stock options and restricted stock units to their executives.
- The vesting schedule of two years is relatively short compared to some companies that use three or four-year vesting periods.
Stakeholder Impact
- Shareholders may view the equity grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of the transaction and grant date of restricted stock awards. |
| 03/13/2024 | Date of signature on the SEC Form 4. |
Keywords
Brainstorm Cell Therapeutics, Chaim Lebovits, restricted stock awards, beneficial ownership, BCLI, SEC Form 4, equity awards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.